This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the recent FDA approval for GSK's TDAP vaccine Boostrix in third trimester pregnancies.

Ticker(s): GSK

Who's the expert?

  • Board certified in both female pelvic medicine and reconstructive surgery and obstetrics and gynecology.
  • Currently manages 10-15 patients per month with IUD's 
  • Has been practicing in the Houston area since 2005 treating women 18 years and older and her primary clinical interests are pelvic floor disorders, urinary incontinence and pelvic organ prolapse. 

Interview Goal
To examine the effects of the FDA's approval for TDAP vaccination in third trimester pregnancies. 

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.